var data={"title":"Triptorelin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Triptorelin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7118?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=triptorelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Triptorelin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231908\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Trelstar Mixject;</li>\n      <li>Trelstar [DSC];</li>\n      <li>Triptodur</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231909\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Decapeptyl;</li>\n      <li>Trelstar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231950\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin Releasing Hormone Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231912\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer (advanced):</b> Trelstar: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3.75 mg once every 4 weeks <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">11.25 mg once every 12 weeks <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">22.5 mg once every 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) (adjunctive therapy): </b> Decapeptyl (Canadian product): Females: SubQ: Usual dose: 0.1 mg once daily initiated on day 2 or 3 or days 21 to 23 of menstrual cycle (or 5 to 7 days prior to expected onset of menses). Dose may be adjusted according to ovarian response as measured by ovarian ultrasound with or without serum estradiol levels. Treatment is continued until follicles achieve suitable size (typically 4 to 7 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial stromal sarcoma (off-label use): </b>IM: 3.75 mg once every 28 days for ~3 to 5 months (Jin 2015). Additional studies are necessary to further define the role of triptorelin in the management of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment of paraphilia/hypersexuality (off-label use) (Guay 2009; Thibaut 1993):</b> Males:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> May cause an initial increase in androgen concentrations, which may be treated with an antiandrogen (eg, flutamide, cyproterone) for 1 to 2 months (Guay 2009). Avoid use in patients with osteoporosis or active pituitary pathology.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Test dose: 1 mg (observe for hypersensitivity); if tolerated, follow with monthly IM injections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 3.75 mg monthly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50724182\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central precocious puberty:</b> Triptodur: Children &ge;2 years and Adolescents: IM: 22.5 mg once every 24 weeks; discontinue therapy at appropriate age of onset of puberty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231913\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15387828\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, renal impairment increases systemic exposure to triptorelin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15387886\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, hepatic impairment increases systemic exposure to triptorelin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231886\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trelstar: 3.75 mg (1 ea [DSC]); 11.25 mg (1 ea [DSC]) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trelstar Mixject: 3.75 mg (1 ea); 11.25 mg (1 ea); 22.5 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted ER, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Triptodur: 22.5 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231870\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15387837\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Subcutaneous, as acetate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decapeptyl: 100 mcg/mL (equivalent to 95.6 mcg triptorelin free base) (1 mL) [prefilled syringe]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231888\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer by IM injection into the buttock (Trelstar) or into the buttock or thigh (Triptodur); alternate injection sites. Administer immediately after reconstitution. Must administer under the supervision of a health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Decapeptyl [Canadian product] is administered by subcutaneous injection into the lower abdomen; alternate injection sites. If a dose is missed, it can be administered on the same day; however, do not double doses. Must administer under the supervision of a health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132735\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For IM preparation, double gloves, a protective gown, and ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) are recommended. Double gloving and a protective gown are required during IM administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231887\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Central precocious puberty: Triptodur:</b> Treatment of central precocious puberty in patients 2 years and older</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer (advanced): Trelstar:</b> Palliative treatment of advanced prostate cancer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Assisted reproductive technologies: Decapeptyl [Canadian product]:</b> Adjunctive therapy in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744918\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Endometrial stromal sarcoma; Paraphilia/hypersexuality; Endometriosis; In vitro fertilization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231877\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Prostate cancer:</b> As reported with all strengths; frequency of effect may vary by strength:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash (59% to 72%), increased serum glucose, increased testosterone (peak: days 2-4; decline to low levels by weeks 3-4)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hemoglobin, decreased red blood cells</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (2% to &gt;10%), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (12% to 13%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Lower extremity edema (6%), hypertension (&le;4%), chest pain (2%), dependent edema (2%), peripheral edema (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 7%), pain (2% to 3%), dizziness (1% to 3%), fatigue (2%), insomnia (1% to &le;2%), emotional lability (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (2%), pruritus (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido (2%), gynecomastia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (3%), anorexia (2%), constipation (2%), dyspepsia (2%), mastalgia (2%), vomiting (2%), abdominal pain (1%), diarrhea (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Erectile dysfunction (10%), testicular atrophy (8%), impotence (2% to 7%), dysuria (5%), urinary retention (&le;1%), urinary tract infection (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Leg pain (2% to 5%), back pain (&le;3%), leg cramps (2%), arthralgia (&le;2%), myalgia (1%), weakness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis (1%), eye pain (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (2%), dyspnea (1%), pharyngitis (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Reproductive studies:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (4% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (9% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginal hemorrhage (2% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Inflammation at injection site (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (4% to 5%), fatigue (3% to 4%), malaise (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Spontaneous abortion (7%), dysmenorrhea (2% to 6%), ovarian hyperstimulation syndrome (3%), hot flash (2%), ovarian cyst (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (3% to 10%), vomiting (3%), abdominal distension (2%), diarrhea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Pelvic pain (6%), gynecological pain (adnexa uteri, 2%), leukorrhea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Pain at injection site (4% to 7%), bruising at injection site (3%), injection site reaction (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Postoperative pain (3% to 4%), back pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (4%), flu-like symptoms (3%), pharyngitis (3%), dyspnea (2%), rhinitis (2%)</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Postmarketing and/or case reports (all indications): Anaphylactic shock, anaphylaxis, angioedema, bladder outflow obstruction, blurred vision, cerebrovascular accident, circulatory shock, deep vein thrombosis, dyspareunia, exacerbation of depression, hematuria, hypersensitivity reaction, increased appetite, limb pain, myocardial infarction, neuropathy, ostealgia, pituitary apoplexy, prolonged Q-T interval on ECG, pulmonary embolism, renal insufficiency, seizure, sleep disorder, spinal cord compression, thrombophlebitis, tissue necrosis at injection site, transient ischemic attacks, tumor flare, urethral obstruction, vaginal dryness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231891\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to triptorelin or any component of the formulation, other GnRH agonists or GnRH; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Breastfeeding women</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231874\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Androgen-deprivation therapy (ADT) may increase the risk for cardiovascular disease (Levine 2010). Myocardial infarction, sudden cardiac death and stroke have been reported in men receiving GnRH agonists. ADT may prolong the QT/QTc interval; consider the benefits of ADT versus the risk for QT prolongation in patients with a history of QTc prolongation, congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients with medications known to prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone density: Use with caution in patients with risk factors for decreased bone mineral density; GnRH agonist therapy may increase risk for osteoporosis and bone fractures particularly with prolonged use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Hyperglycemia and an increased risk of developing diabetes has been reported with therapy and may manifest as diabetes or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA<sub>1c</sub>) as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Angioedema and anaphylactic shock have occurred; discontinue use if severe reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian hyperstimulation syndrome: Decapeptyl [Canadian product]: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric effects: Symptoms of emotional lability (eg, crying, irritability, anger, aggression, impatience) have been reported with GnRH agonists, including triptorelin; monitor for the development or worsening of psychiatric symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been reported with GnRH agonists, including triptorelin in patients with or without a history of seizures or other conditions or concurrent medications associated with seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal cord compression: Cases of spinal cord compression, which may contribute to weakness or paralysis (possible fatal complications), have been reported; observe patients with metastatic vertebral lesions closely during the first few weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Symptom flare: Transient initial increases in gonadotropins and sex steroids leading to a worsening of symptoms may be observed during the first few weeks of therapy or after subsequent doses. Patients with prostate cancer may experience new or increased bone pain, neuropathy, hematuria, or urethral or bladder outlet obstruction. Female patients with central precocious puberty may experience transient vaginal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary tract obstruction: Observe patients with urinary tract obstruction closely during the first few weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300181\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231879\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10018&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231882\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231893\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in pregnant women. When used for ART, pregnancy must be ruled out prior to therapy and nonhormonal contraception should be used until menses occurs. Due to the short half-life of triptorelin (formulations used for ART), it is not expected to be present in the maternal serum at the time of embryo transfer. In case reports, spontaneous abortion, congenital anomalies, and other adverse events have been reported following triptorelin (Decapeptyl [Canadian product]) exposure during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17963551\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if triptorelin is present in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231884\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucose and HbA<sub>1c</sub> (periodically), signs and symptoms of emerging cardiovascular disease; consider periodic monitoring of electrocardiograms and electrolytes in at-risk patients; development/worsening of psychiatric symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional monitoring (per indication):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of precocious puberty: Monitor response to therapy with LH levels after a GnRH or GnRH agonist stimulation test, basal LH, or serum sex steroid levels beginning 1 to 2 months after initiation of therapy, during therapy, and with each subsequent dose; height every 3 to 6 months; bone age (periodically)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prostate cancer: Serum testosterone levels, prostate-specific antigen; bone density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Assisted reproductive technologies: Decapeptyl [Canadian product]: Negative pregnancy test prior to initiation of therapy; signs/symptoms of allergic reaction for 30 minutes after administration; ultrasound and/or estradiol levels to assess follicle development; ultrasound to assess number and size of follicles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Treatment of paraphilia/hypersexuality (off-label use): The following monitoring has been recommended for other GnRH agonists: CBC (baseline, monthly for 4 months then every 6 months); serum testosterone (baseline, monthly for 4 months then every 6 months); serum LH (baseline and every 6 months), FSH (baseline), serum BUN and creatinine (baseline and every 6 months); bone density (baseline and yearly); ECG (baseline) (Reilly 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231873\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Triptorelin is an agonist analog of gonadotropin releasing hormone (GnRH) and causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels. After chronic and continuous administration, usually 2 to 4 weeks after initiation, a sustained decrease in LH and FSH secretion occurs. When used for ART, prevents premature LH surge in women undergoing controlled ovarian hyperstimulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231890\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 30 to 33 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Unknown; unlikely to involve CYP; no known metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2.8 &plusmn; 1.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate-to-severe renal impairment: 6.6 to 7.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment: 7.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Trelstar: 1 to 3 hours; Triptodur: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (42% as intact peptide); hepatic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324043\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Trelstar Mixject Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.75 mg (1): $975.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.25 mg (1): $2,927.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg (1): $5,855.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Reconstituted ER</b> (Triptodur Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg (1): $19,200.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F231894\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arvekap (GR);</li>\n      <li>Decapeptyl (AE, AR, BE, BG, BH, CL, CN, CO, CY, CZ, DE, EC, EG, ES, FR, GB, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, OM, PL, PT, PY, RU, SA, SK, SY, TR, UY, VE, YE);</li>\n      <li>Decapeptyl CR (AE, BH, CY, EG, HR, IL, IQ, IR, JO, KR, KW, LB, LY, MY, NZ, OM, PH, QA, SA, SG, SY, TH, YE);</li>\n      <li>Decapeptyl Daily (IN);</li>\n      <li>Decapeptyl Depot (AT, CZ, DE, DK, EE, FI, IN, IS, KR, LT, SE, SK);</li>\n      <li>Decapeptyl LA (EC);</li>\n      <li>Decapeptyl LP (FR);</li>\n      <li>Decapeptyl Retard (CH);</li>\n      <li>Decapeptyl SR (PK);</li>\n      <li>Decapetyl (LK);</li>\n      <li>Diphereline (AU, LV, RO, SG, TH, VN);</li>\n      <li>Diphereline PR (HK, KR, MY, PH, TH, TW);</li>\n      <li>Dyferelin (UA);</li>\n      <li>Gonapeptyl (AE, FR, GB, IE, JO, LB, MT, PY, RO, VN);</li>\n      <li>Gonapeptyl CR (BH, QA);</li>\n      <li>Gonapeptyl Daily (BR, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gonapeptyl Depot (CR, CU, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gonapeptyl,CR (LB);</li>\n      <li>GonapeptylCR (SA);</li>\n      <li>Neo Decapeptyl (BR);</li>\n      <li>Neo-Decapeptyl CR (PE);</li>\n      <li>Pamorelin (CR, DO, GT, HN, NI, NO, PA, PH, SV);</li>\n      <li>Salvacyl (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3960626\"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19959075\"></a>Amant F, Coosemans A, Debiec-Rychter M, et al. Clinical management of uterine sarcomas. <i>Lancet Oncol</i>. 2009;10(12):1188-1198. doi: 10.1016/S1470-2045(09)70226-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/19959075/pubmed\" target=\"_blank\" id=\"19959075\">19959075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15516445\"></a>Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. <i>Obstet Gynecol.</i> 2004;104(5 Pt 2):1182-1184. doi: 10.1097/01.AOG.0000133533.05148.aa.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/15516445/pubmed\" target=\"_blank\" id=\"15516445\">15516445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6423951\"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decapeptyl (triptorelin) [product monograph]. North York, Ontario, Canada: Ferring Inc; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22997462\"></a>ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii92-vii99. doi: 10.1093/annonc/mds253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/22997462/pubmed\" target=\"_blank\" id=\"22997462\">22997462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/22531097/pubmed\" target=\"_blank\" id=\"22531097\">22531097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. <i>Clin Ther</i>. 2009;31(1):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/19243704/pubmed\" target=\"_blank\" id=\"19243704\">19243704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12534540\"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26131171\"></a>Jin Y, Li Y, Deng CY, et al. Fertility-sparing treatment of low-grade endometrial stromal sarcoma. <i>Int J Clin Exp Med</i>. 2015;8(4):5818-5821.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/26131171/pubmed\" target=\"_blank\" id=\"26131171\">26131171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Society of Obstetricians and Gynaecologists of Canada -Canadian Fertility and Andrology Society (SOGC-CFAS ) Clinical Practice Guidelines Committee, Shmorgun D, Claman P, Gysler M, et al. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/22416285/pubmed\" target=\"_blank\" id=\"22416285\">22416285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association,&rdquo; <i>Circulation</i>, 2010, 121:831-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10985636\"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo; <i>Can J Psychiatry</i>, 2000, 45(6):559-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/10986575/pubmed\" target=\"_blank\" id=\"10986575\">10986575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7746084\"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thibaut F, Cordier B, and Kuhn JM, &ldquo;Effect of a Long-Lasting Gonadotrophin Hormone-Releasing Hormone Agonist in Six Cases of Severe Male Paraphilia,&rdquo; <i>Acta Psychiatr Scand</i>, 1993, 87(6):445-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/8356897/pubmed\" target=\"_blank\" id=\"8356897\">8356897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM; WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. <i>World J Biol Psychiatry</i>. 2010;11(4):604-655.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/triptorelin-drug-information/abstract-text/20459370/pubmed\" target=\"_blank\" id=\"20459370\">20459370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trelstar (triptorelin) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trelstar (triptorelin) [product monograph]. Markham, Ontario, Canada: Allergan Pharma Co; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Triptodur (triptorelin) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10018 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F231908\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F231909\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F231950\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F231912\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50724182\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F231913\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15387828\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15387886\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F231886\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F231870\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F15387837\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F231888\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132735\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F231887\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744918\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F231877\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F231891\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F231874\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300181\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F231879\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F231882\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F231893\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17963551\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F231884\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F231873\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F231890\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324043\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F231894\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10018|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=triptorelin-patient-drug-information\" class=\"drug drug_patient\">Triptorelin: Patient drug information</a></li></ul></div></div>","javascript":null}